JADENU's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9283209 | NOVARTIS PHARMS CORP | Oral formulations of deferasirox |
Nov, 2034
(11 years from now) | |
Jadenu is owned by Novartis Pharms Corp.
Jadenu contains Deferasirox.
Jadenu has a total of 1 drug patent out of which 0 drug patents have expired.
Jadenu was authorised for market use on 30 March, 2015.
Jadenu is available in tablet;oral dosage forms.
The generics of Jadenu are possible to be released after 21 November, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M (M) | Jul 23, 2023 |
Drugs and Companies using DEFERASIROX ingredient
Market Authorisation Date: 30 March, 2015
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of JADENU before it's drug patent expiration?
More Information on Dosage
JADENU family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic